News
In this category you will find the latest insights from evitria as well as current press releases.
Articles about News (14)
-
Bispecific Antibodies: Commercial Successes and Research Feasibility
In the past 10 years, the use of bispecific antibodies – proteins capable of engaging two targets simultaneously – has become a key focus area for the industry. Read all about their success and research feasibility in this article.
-
Press release: Genovis AB enters service agreement with evitria AG for fast LC-MS analysis of recombinant antibodies
Genovis AB and evitria AG signed a service agreement to offer evitria’s customers fast LC-MS characterization of recombinant antibodies using Genovis proprietary enzyme technologies. evitria AG is a world leading service provider for recombinant antibody expression in CHO cells, with headquarters in Zürich, Switzerland.
-
Press release: evitria promotes Director of Client Relations, Richard Park, to Global Head of Client Relations & Business Development
evitria AG, a Zurich, Switzerland-based contract research, development, and manufacturing organization focused on transient recombinant antibody and protein production, announced that former Director of Client Relations, Richard Park, has been appointed Global Head of Client Relations and Business Development.
-
Press release: evitria AG announces license of mAbsolve STR technology
evitria AG, a research, development, and manufacturing organization focused on transient recombinant antibody and protein production, announces the closing of a license agreement with mAbsolve Ltd for mAbsolve’s proprietary STR technology.
